Stock comparison
BrainsWay
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BWAY
BrainsWay
Market cap
$592.27M
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BWAY | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 65C | GMAB |
| Benjamin Graham | 70D | 64C | BWAY |
| Philip Fisher | 57C | 48D | BWAY |
| Peter Lynch | 52C | 25F | BWAY |
| Joel Greenblatt | 46D | 76B | GMAB |
| Charlie Munger | 41D | 68C | GMAB |
| Terry Smith | 52D | 71C | GMAB |
Side-by-side metrics
| Metric | BWAY | GMAB |
|---|---|---|
| Market cap | $592.27M | $16.5B |
| P/E (TTM) | 75.0x | 6.2x |
| EV/EBIT | 123.9x | 12.0x |
| ROIC (TTM) | 5.05% | 43.78% |
| Gross margin | 75.42% | 93.88% |
| Net margin | 13.5% | 18.23% |
| Revenue CAGR 5y | 15.42% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BWAY leads on
- Revenue CAGR 5y15.42%vs -18.45%+184%
GMAB leads on
- Market cap$16.5Bvs $592.27M+96%
- P/E (TTM)6.2xvs 75.0x+92%
- EV/EBIT12.0xvs 123.9x+90%
- ROIC (TTM)43.78%vs 5.05%+88%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.